...
首页> 外文期刊>Breast cancer >miR-668 enhances the radioresistance of human breast cancer cell by targeting IκBα
【24h】

miR-668 enhances the radioresistance of human breast cancer cell by targeting IκBα

机译:miR-668通过靶向IκBα增强人类乳腺癌细胞的放射抵抗力

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background A large proportion of breast cancer patients are resistant to radiotherapy, which is a mainstay treatment for this malignancy, but the mechanisms of radioresistance remain unclear.Methods and materialsTo evaluate the role of miRNAs in radioresistance, we established two radioresistant breast cancer cell lines MCF-7R and T-47DR derived from parental MCF-7 and T-47D. Moreover, miRNA microarray, quantitative RT-PCR analysis, luciferase reporter assay and western blotting were used.ResultsWe found that miR-668 was most abundantly expressed in radioresistant cells MCF-7R and T-47DR. miR-668 knockdown reversed radioresistance of MCF-7R and T-47DR, miR-668 overexpression enhanced radioresistance of MCF-7 and T-47D cells. Mechanically, bioinformatics analysis combined with experimental analysis demonstrated IκBα, a tumor-suppressor as well as an NF-κB inhibitor, was a direct target of miR-668. Further, miR-668 overexpression inhibited IκBα expression, activated NF-κB, thus, increased radioresistance of MCF-7 and T-47D cells. Conversely, miR-668 knockdown restored IκBα expression, suppressed NF-κB, increased radiosensitivity of MCF-7R and T-47DR cells.ConclusionOur findings suggest miR-668 is involved in the radioresistance of breast cancer cells and miR-668-IκBα-NF-κB axis may be a novel candidate for developing rational therapeutic strategies for human breast cancer treatment.
机译:背景技术大部分乳腺癌患者对放疗有抵抗力,这是该恶性肿瘤的主要治疗方法,但放射抵抗的机制仍不清楚。 -7R和T-47DR衍生自亲本MCF-7和T-47D。结果,我们发现miR-668在抗放射细胞MCF-7R和T-47DR中表达最丰富。 miR-668敲低可逆转MCF-7R和T-47DR的放射线,miR-668过表达可增强MCF-7和T-47D细胞的放射线。从机械上讲,生物信息学分析与实验分析相结合证明,肿瘤抑制因子IκBα和NF-κB抑制剂是miR-668的直接靶标。此外,miR-668过表达抑制IκBα表达,激活NF-κB,因此增加了MCF-7和T-47D细胞的放射抵抗力。相反,miR-668敲低恢复了IκBα表达,抑制了NF-κB,增加了MCF-7R和T-47DR细胞的放射敏感性。 -κB轴可能是开发用于人类乳腺癌治疗的合理治疗策略的新候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号